Study shows ReWalk exoskeleton maintains long-term home use
Lifeward Ltd. (LFWD) published a study on long-term use of its ReWalk Personal Exoskeleton, showing positive results in seven individuals with chronic paraplegia. The study, conducted by Andrea Giovanni Cutti and colleagues, reported no falls or fractures, with participants walking a median distance of 129 meters in a six-minute test. The exoskeleton is FDA-cleared and CE Marked, covered by Medicare for eligible beneficiaries.
How this was made
The 30-second read
Why it matters
The study provides the first long‑term safety and efficacy data, which could influence investor sentiment and payer decisions.
Market read
Positive clinical outcomes may enhance LFWD's growth outlook and affect its stock price.
What to watch
Reimbursement policies, competition from other exoskeleton manufacturers, and the need for larger clinical trials.
Background
LFWD (NASDAQ:LFWD) develops wearable robotic exoskeletons for spinal‑cord injury patients. The ReWalk device is FDA‑cleared and Medicare‑covered.
Ticker impact
LFWD announced publication of a peer‑reviewed study showing long‑term home use of its ReWalk exoskeleton with positive safety and functional outcomes.
likely upward pressure as investors price in potential sales growth and Medicare coverage expansion.
The study is the first public disclosure of long‑term real‑world results, a material data point for a medical‑device company, but the financial impact is uncertain.
Market effects
May boost confidence in the assistive‑technology and medical‑device sector.
Potentially positive for U.S. healthcare investors and Medicare‑related reimbursement discussions.
Limited to markets where ReWalk is approved; modest global relevance.
Counterpoint
The study size is small (seven participants) and may not translate into significant revenue growth.
Key entities
- CompanyLifeward Ltd.
Developer of the ReWalk exoskeleton.
- ResearcherAndrea Giovanni Cutti
Lead author of the study.
